- Patent Title: Oligomeric compounds comprising alpha-beta-constrained nucleic acid
-
Application No.: US15305451Application Date: 2015-04-24
-
Publication No.: US10221416B2Publication Date: 2019-03-05
- Inventor: Michael Oestergaard , Eric E. Swayze , Punit P. Seth
- Applicant: Ionis Pharmaceuticals, Inc.
- Applicant Address: US CA Carlsbad
- Assignee: Ionis Pharmaceuticals, Inc.
- Current Assignee: Ionis Pharmaceuticals, Inc.
- Current Assignee Address: US CA Carlsbad
- Agency: McNeill Baur PLCC
- International Application: PCT/US2015/027439 WO 20150424
- International Announcement: WO2015/164693 WO 20151029
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C12N15/113 ; C12N15/11

Abstract:
The present disclosure provides oligomeric compounds comprising at least one α-β-constrained nucleic acid as provided herein. More particularly, the α-β-constrained nucleic acid provided herein comprise an optionally modified nucleoside with a phosphorus containing constrained internucleoside linkage such as for example a cyclic phosphate internucleoside linkage. The α-β-constrained nucleic acid provided herein are expected to be useful for enhancing one or more properties of oligomeric compounds they are incorporated into such as for example nuclease resistance. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
Public/Granted literature
- US20170044539A1 OLIGOMERIC COMPOUNDS COMPRISING ALPHA-BETA-CONSTRAINED NUCLEIC ACID Public/Granted day:2017-02-16
Information query